Jessica Jensen
Direttore Tecnico/Scientifico/R&S presso POINT Biopharma, Inc. (United States)
Posizioni attive di Jessica Jensen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Direttore Tecnico/Scientifico/R&S | 01/08/2020 | - |
Storia della carriera di Jessica Jensen
Precedenti posizioni note di Jessica Jensen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| POIT BIOP | Direttore Tecnico/Scientifico/R&S | 30/06/2021 | 27/12/2023 |
| PROGENICS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2018 | 01/08/2020 |
Formazione di Jessica Jensen
| George Washington University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| POIT BIOP | Health Technology |
| Aziende private | 2 |
|---|---|
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Commercial Services |
- Borsa valori
- Insiders
- Jessica Jensen
- Esperienza